Revised SPC: Crysvita (burosumab) 20 mg solution for injection

This is now approved for the treatment of X-linked hypophosphataemia in adults (previously indicated only in children and adolescents with radiographic evidence of bone disease). Various sections have been updated to reflect data on use in adults.

Source:

electronic Medicines compendium